See more : Cubtek Inc. (2252.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Sharps Technology, Inc. (STSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sharps Technology, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- EXEO Group, Inc. (1951.T) Income Statement Analysis – Financial Results
- adesso SE (ADN1.DE) Income Statement Analysis – Financial Results
- China Mengniu Dairy Company Limited (CIADY) Income Statement Analysis – Financial Results
- Migao Grp Hldg Ltd (9879.HK) Income Statement Analysis – Financial Results
- ProVen Growth & Income VCT PLC (PGOO.L) Income Statement Analysis – Financial Results
Sharps Technology, Inc. (STSS)
About Sharps Technology, Inc.
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 891.25K | 654.57K | 28.70K | 11.04K | 10.59K |
| Gross Profit | -891.25K | -654.57K | -28.70K | -11.04K | -10.59K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.61M | 2.28M | 1.69M | 827.01K | 388.02K |
| General & Administrative | 8.52M | 6.46M | 2.81M | 1.51M | 1.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 1.66M |
| SG&A | 8.52M | 6.46M | 2.81M | 1.51M | 1.66M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.13M | 8.74M | 4.50M | 2.33M | 2.05M |
| Cost & Expenses | 10.13M | 8.74M | 4.50M | 2.33M | 2.06M |
| Interest Income | 0.00 | 1.32K | 769.00 | 3.33K | 3.60K |
| Interest Expense | 138.12K | 1.32M | 167.52K | 0.00 | 0.00 |
| Depreciation & Amortization | 891.25K | 654.57K | 28.70K | 11.04K | 10.59K |
| EBITDA | -8.98M | -2.66M | -4.47M | -2.33M | -2.04M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.13M | -8.74M | -4.50M | -2.33M | -2.06M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 255.01K | 4.10M | -166.75K | -6.87K | 3.59K |
| Income Before Tax | -9.87M | -4.64M | -4.66M | -2.34M | -2.06M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -30.00K | -5.42M | 166.75K | 6.87K | 3.00 |
| Net Income | -9.84M | 779.89K | -4.83M | -2.35M | -2.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.76 | 0.10 | -0.53 | -0.26 | -0.22 |
| EPS Diluted | -0.76 | 0.10 | -0.53 | -0.26 | -0.22 |
| Weighted Avg Shares Out | 13.03M | 8.10M | 9.17M | 9.17M | 9.17M |
| Weighted Avg Shares Out (Dil) | 13.03M | 8.10M | 9.17M | 9.17M | 9.17M |
UPDATE - Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement...
Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement...
Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals
$50 Million acquisition of InjectEZ strengthens manufacturing capacity and establishes Sharps' leading position in the specialized copolymer prefillable syringe system industry Signed term sheet providing for up to $75 Million in debt financing to be used for the acquisition Nephron...
Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales
Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market
Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
What You Need to Know About Buying Penny Stocks in 2022
Check these tips out for trading penny stocks in 2022 The post What You Need to Know About Buying Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports